HopeStage
Back to all studies
CompletedNCT00563706

Vabicaserin or placebo for acute schizophrenia symptoms

About this titleRead the official source — NCT00563706

Researchers compared vabicaserin, risperidone and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.

Medication studyAges 18–65United States + Canada
The study in practice

Understand this study

What did researchers investigate?

Researchers compared vabicaserin, risperidone and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Little Rock and 32 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateDecember 2007
Recruitment status
Completed
Enrollment listed in the registry
199
Sponsor
Pfizer
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Canada
Age range
From 18 Years to 65 Years
Official registry ID
NCT00563706
Official title
Show the full official title

A Randomized, Double-Blind, Placebo-Controlled, Risperidone-Referenced, Parallel-Group, Adaptive-Design Study of the Efficacy, Safety, and Tolerability of Vabicaserin (SCA-136) in Subjects With Acute Exacerbations of Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Little Rock, United States · Cerritos, United States · Escondido, United States

28 more locations
  • Garden Grove, United States
  • Glendale, United States
  • San Diego, United States
  • Torrance, United States
  • Washington D.C., United States
  • Aventura, United States
  • Hollywood, United States
  • Kissimmee, United States
  • Hoffman Estates, United States
  • Indianapolis, United States
  • Lake Charles, United States
  • Baltimore, United States
  • Rockville, United States
  • Hamilton, United States
  • Willingboro, United States
  • Cedarhurst, United States
  • Holliswood, United States
  • New York, United States
  • Butner, United States
  • Oklahoma City, United States
  • Philadelphia, United States
  • Austin, United States
  • Bellaire, United States
  • DeSoto, United States
  • Houston, United States
  • Arlington, United States
  • Portsmouth, United States
  • Kingston, Canada

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared vabicaserin, risperidone and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.

Who is behind this study?

The study sponsor is Pfizer.

Did this study involve medication?

Yes. The study involved medication, including vabicaserin and risperidone.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies